Clinical Neuroscience

Multimodality teratment of anaplastic supratentorial gliomas with high-dose dibromodulcitol and dibromodulcitol plus BNCU (a pilot study)

ÁFRA Dénes1, MAYER Árpád1, SÍPOS László2

NOVEMBER 20, 1993

Clinical Neuroscience - 1993;46(11-12)

A pilot study with a high dose DBD, and DBD plus BCNU therapy for the treatment of malignant gliomas has been performed. Radiotherapy combined with DBD in a dose of 700 mg/sqm/week was administred to 27 patients after extensive removal of supratentorial anaplastic astrocytomas and glioblastomas. Subsequently, DBD in a dose of 1400 mg/sqm was given monthly to a group of nine patients and another thirteen patients received DBD plus BCNU on two consecutive days in a dose of 1000 mg/sqm and 150 mg/sqm, every 6-8 weeks. Both kinds of chemotherapy have been well tolerated, no patient died because of toxic side effect. Following the first dose of DBD and BCNU such a severe myelotoxicity occurred in one case that treatment was discontinued but the patient recovered completely. The high-dose DBD treatment proved to be markedly effective against glioblastomas, while the combination of DBD and BCNU showed more pronounced activity against anaplastic astrocytomas. As the results were promising, accordingly further extensive studies seem to be worthwhile.

AFFILIATIONS

  1. Országos Idegsebészeti Tudományos Intézet, Budapest
  2. Onkoradiológiai Központ, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[In Memoriam György Bekény]

HORVÁTH Sándor

[After a life of struggle and success, and after a serious illness borne with dignity and discipline, death took him at the age of seventy-eight. Even in the last years of his life, ill but tireless, he served his vocation with his knowledge: healing and teaching; patients and interested students; the Clinic. Shortly before his death, he completed his last scientific work, The History of Hungarian Neurology.]

Clinical Neuroscience

[The illogical therapy]

SZIRMAI Imre, SUREK György, KAMONDI Anita, MAGYAR Hedvig, JUHÁSZ Csaba

[Most of the causative pathological factors in ischemic cerebrovascular events cannot be recognized during the acute stage of the disease partly because of to the complexity of biophysical model of cerebral microcirculation, partly because the causative factors in this model cannot be confidently weighted. Clinical diagnoses on cerebral circulation disorders are based on the fundamental causes of the disorders. Evoking factors are hypotheses, consequently therapies are directed to hypotheses. The mathematical model of cerebral microcircualtion is mondeterministic. The interactions between vascular factors and blood fluidity can be roughly estimated. Judging the therapeutic efficacy is hindered by the nondeterministic disease model, the indefinite clinical clues, their individual variations, heterogenous diagnostic groups, and tendency of spontaneous restoration of symptoms. Non-specific drugs are used to treat cerebral ischemia, and trials making use of monotherapies have failed to change the life expectancy or the clinical course of ischemic patients. The acute stage of the disease cannot be defined and because of the incompleteness of clinical indicators „stroke prevention" appeares to be ambiguious. Therefore, the nature of the treatment of ischemic cerebrovascular disease is at present based on trial and error.]

Clinical Neuroscience

[Molecular characterization of the T cell receptor in experimental allergic encephalomyelitis and multiple sclerosis - new therapeutical approaches]

KÁLMÁN Bernadett, LUBLIN D. Fred

[The authors review here the most recent literature on experimental allergic encephalomyelitis and multiple sclerosis, focusing on the efferent branch of the immune response. They attempt to describe the molecular characteristics of the myelin antigen specific T cell receptors. Identification of the most distinct properties of the disease mediating cells may not only provide clues to the etiology of MS, but also opens new avenues to specific therapeutical approaches.]

Clinical Neuroscience

[Experimential allergic encephalomyelitis multiplex sclerosis!]

KAPÓCS Gábor

[T-lymphocytes and molecular engineering]

Clinical Neuroscience

[Transcranial doppler of extracranial stenosis in internal carotid artery]

NAGY Valéria, BEDŐ György

[Endeavours were made to determine why mean velocity and pulsatility index changes in middle and anterior cerebral artery are caused by the unilateral occlusion of the internal carotid artery or by severe stenosis. The transcranial Doppler method is suitable for judgingre pathologic intracranial blood flow conditions, especially when data are compared to those of healthy conditions.]

All articles in the issue

Related contents

Clinical Oncology

[Cancer-treatment induced peripheral neuropathy]

DEMETER Gyula

[Peripheral neuropathy is caused by structural or functional damage of nervous system. The pathophysiology is not well known. Its clinical features are established but there is a need to standardize CIPN assessment, also considering that health care providers and patients frequently have a different perception of CIPN severity. Neurotoxicity caused by traditional chemotherapy is widely recognized in patients with cancer. The adverse effects of newer therapeutics, such as targeting and immunotherapeutic agents, need more information for the proper management. This review addresses the main neurotoxicities of cancer treatments with a focus on the newer therapeutics. Recognition of these patterns of toxicity is important because drug discontinuation or dose adjustment might prevent further neurological injury. Treatment is symptomatic. For prevention or treatment there is need for further basic research outcomes.]

Clinical Neuroscience

[Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas]

SIPOS László, VITANOVICS Dusan, ÁFRA Dénes

[Introduction - Anaplastic astrocytomas and glioblastomas are the most frequent and most malignant hemispherial tumours. Unfortunately, astrocytic tumours are of infiltrative character and radical removal is not possible. Recurrent malignant gliomas are rarely suitable for reoperation. In most of the cases of recurrent gliomas chemotherapy is the last choice. Patients and method - Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month. The patients received two to 16 courses of chemotherapy. The toxicity, quality of life, response to chemotherapy and survival data were analysed. Results - Out of 75 patients four were excluded following the first treatment due to myelotoxicity, and allergic reactions. Among the patients treated with temozolomide in seven cases complete response, 17 partial response, 14 progressive disease were observed. In 33 cases the disease stabilized and out of them in 27% a significant neurological improvement was detected. The time to progression was 6.8 months and the median survival time 8.75 months for patients with glioblastoma and with malignant astrocytoma or malignant mixed oligoastrocytoma 9.45 and 11.15 months, respectively. The overall survival for patients with originally lower grade glioma was 70.32 and for patients with glioblastoma multiforme 17.43 months. Conclusions - Temozolomide chemotherapy in patients with recurrent malignant astrocytoma and glioblastoma proved to be efficacious and similar good results were achieved as with a nitrosourea based combined chemotherapy. Even in those patients who received previous chemotherapy temozolomide is well tolerated and a relatively long time to progression was achieved in cases of recurrent malignant gliomas. In a few number of patients where BCNU had been previously failed with temozolomide stable disease was achieved. Temozolomide seems to be a promising drug in the chemotherapy of malignant gliomas and can be applied as a second line chemotherapy, as well.]

Clinical Oncology

[Neoadjuvant treatment of rectal cancer]

PINTÉR Tamás

[Rectal cancer due to its frequent local invasion, high recurrence rate and metastatic potential is a serious health problem, leading to decreased life quality, severe complaints and death. Treatment for locally advanced, resectable rectal cancer improved over the years. Various chemotherapy protocols and combinations with radiation therapy and radical surgery - total mesorectal excision (TMA) - are the main elements of current therapy. Preoperative combined chemoradiation followed by surgery is the preferred treatment sequence. Radiation treatment in combination with fl uoropyrimidines (infusional 5-fl uorouracil [5-FU] or oral capecitabine) is recommended. Clinical trials with oxaliplatin-based neoadjuvant chemoradiation did not improve the pathologic complete response rate (pCR). Oxaliplatin-based treatment was more toxic as compared with 5-FU. The data concerning local recurrence rate and survival are controversial. Adjuvant chemotherapy in some studies improved survival, so - based on positive results in colon cancer - adjuvant FOLFOX chemotherapy may be recommended.]

Clinical Oncology

[Oncological management of gastro-entero-pancreatic neuroendocrine neoplasias]

PETRÁNYI Ágota, UHLYARIK Andrea, RÁCZ Károly, BODOKY György

[Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are unusual and relatively rare neoplasms. They characteristically synthetize, store and secrete a variety of peptides and neuroamines, which can lead to development of disctinct clinical syndromes. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. The diagnosis of NETs is established by histological examination and the immunohistochemical detection of general neuroendocrine markers, such as chromogranin A (CgA) and synaptophysin. An update of the WHO classifi cation has resulted in a new classifi cation dividing neuroendocrine neoplasms into neuroendocrine tumors (NETs) including G1 (Ki67 index ≤2%) and G2 (Ki67 index 3-20%) tumors and neuroendocrine carcinomas (NECs) with Ki67 index >20%, G3. The different available therapeutic approaches, including surgery, liver-directed ablative therapies, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, are discussed in this overview.]

Clinical Oncology

[Recent strategies in the chemoterapy of soft tissue tumors]

PÁPAI Zsuzsanna, KISS Nóra

[Conventional adjuvant therapy is, in most cases, either the well-known standard doxorubicin monotherapy or the combination of doxorubicin + ifosfamide. No clear guideline has been developed yet - adjuvant therapy is recommended in cases with high grade, larger than 10 cm, sarcoma, where surgery hasn’t been suffi ciently radical, and adjuvant radiotherapy may not be advisable. In locally advanced tumors, due to the requirements of limb salvage, isolated limb perfusion is recommended. As a new compound, hafnium-oxide nanoparticles (NBTXR3) can be useful in local therapy: combining intratumoral injection and radiotherapy may be a fl agship initiative, however further investigations are necessary. In the treatment of metastatic tumors, beside the standard methods, new, targeted treatments are becoming more and more prevalent: in leiomyosarcomas trabectedine, pazopanib and olaratumab; in liposarcomas trabectedine and eribulin; in synovial sarcomas pazopanib; and in imatinib-resistant GIST, sunitinib and regorafenib. Soft tissue sarcomas are rare tumors categorized as heterogeneous histological subtypes. In their treatment, it is key to customize the treatment based on these subtypes and interdisciplinary collaboration with the orthopedic surgeon, the pathologist and the radiotherapist to determine the suitable therapy for each individual.]